Home | Contact | Sitemap | Santen Worldwide

Text Size

A
A
A

What's New

News Release

Sep 21, 2018 Santen and Ube Industries Announce Receipt of Manufacturing and Marketing Approval for Glaucoma and Ocular Hypertension Treatment EYBELIS in Japan
Sep 21, 2018 Santen Files for Manufacturing and Marketing Approval of Anti-Allergy Ophthalmic Drug Candidate DE-114A (JAN: Epinastine Hydrochloride)
Sep 13, 2018 Personnel Changes of Corporate Officer
Sep 12, 2018 Personnel Changes of Representative Director of the Board
Aug 1, 2018 Santen Reports the 1st Quarter Fiscal 2018 Consolidated Performance
Jul 26, 2018 Notice on Completion of Payment for Issuance of New Shares Under Restricted Stock-linked Remuneration Program
Jul 17, 2018 Santen Donates to Japan Flood and Landslide Relief Efforts
Jul 10, 2018 Santen Receives Marketing Authorisation from the European Commission for DE-076C (Verkazia) as an Orphan Medicinal Product
Jun 28, 2018 Corporate Social Responsibility (CSR) page on our website has been updated
Jun 26, 2018 Notice on the Issuance of New Shares Under Restricted Stock-Linked Remuneration Program
Jun 4, 2018 Santen Announces Medium-Term Plan (MTP2020)
May 9, 2018 Notice of Board of Director and Corporate Auditor Nominations
May 9, 2018 Santen Reports Fiscal 2017 Consolidated Performance
May 9, 2018 Notice on the Introduction of a New Stock-Linked Remuneration Program and Change to Director Remuneration
Mar 29, 2018 CSR page on our website has been updated
Mar 14, 2018 Notice of Corporate Officer Appointments
Feb 23, 2018 Santen to Conduct a Public Awareness Campaign for Glaucoma During World Glaucoma Week March 11 - 17
Feb 20, 2018 Santen Awarded for Corporate Governance
Feb 20, 2018 Santen Announces Appointment of New President
Feb 6, 2018 Santen Reports the 3rd Quarter Fiscal 2017 Consolidated Performance

Working at Advanced Vision Science